BI-1808

PreclinicalSmall molecule

BBioInvent International AB

BI-1808 is one of 43 small molecule programs targeting Advanced Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MalignanciesRecruiting

Advanced MalignanciesPreclinical

Recruiting

Competition

Competitive Landscape

53 competitors in Advanced Malignancies

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 3

2 2

Beyfortus

BeiGene

Phase 3

1 3

Elunate

Takeda

Phase 3

1 4

Zaniducla

Jazz Pharmaceuticals

Phase 3

1 5

Talzenna

Pfizer

Phase 3

1 6

Alimta

SShawn Eagle

Phase 3

5 7

Keytruda

Merck & Co.

Phase 2

14 8

Bavencio

EMD Serono

Phase 3

3 9

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 10

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Advanced Malignancies

NCT04752826

Clinical

Trials by Indication[1]

Advanced Malignancies1 trial

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies

Recruiting·BBioInvent International AB·Preclinical·NCT04752826·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BI-1808. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BI-1808 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BI-1808. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioInvent International AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBioInvent International AB

BI-1808

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Advanced Malignancies1 trial

References

Drug Info

Quick Facts

Related News